Jeffrey Rydin Net Worth

The estimated Net Worth of Jeffrey P Rydin is at least $3.23 million dollars as of 10 May 2022. Mr. Rydin owns over 100,000 units of Alphatec Inc stock worth over $2,861,844 and over the last 19 years he sold ATEC stock worth over $261,368. In addition, he makes $110,788 as Director at Alphatec Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Rydin ATEC stock SEC Form 4 insiders trading

Jeffrey has made over 35 trades of the Alphatec Inc stock since 2007, according to the Form 4 filled with the SEC. Most recently he exercised 100,000 units of ATEC stock worth $200,000 on 10 May 2022.

The largest trade he's ever made was exercising 100,000 units of Alphatec Inc stock on 10 May 2022 worth over $200,000. On average, Jeffrey trades about 7,092 units every 103 days since 2005. As of 10 May 2022 he still owns at least 525,109 units of Alphatec Inc stock.

You can see the complete history of Mr. Rydin stock trades at the bottom of the page.

Jeffrey Rydin biography

Jeffrey P. Rydin serves as Director of the Company. Prior to joining the Board of Directors, Mr. Rydin served as a Special Advisor to the Board of Directors from September 2016 to June 2017. Mr. Rydin has spent nearly 30 years in the medical device and healthcare industries. Prior to joining Alphatec as Special Advisor to the Board of Directors, Mr. Rydin served as Chief Sales Officer of Ellipse Technologies, Inc., a medical technology company, from September 2015 until its purchase by NuVasive, Inc. in February 2016. Before joining Ellipse, Mr. Rydin served as President of Global Sales at NuVasive, Inc. (October 2011 to March 2013), where he was responsible for NuVasive, Inc.’s worldwide sales efforts, including the oversight of strategic sales development, sales administration, Area Vice Presidents and sales training. Prior to his position of President of Global Sales, he served as Executive Vice President of Sales-Americas and Senior Vice President, U.S. Sales since joining NuVasive, Inc. in December 2005. Prior to joining NuVasive, Mr. Rydin served as Area Vice President, Sales (US Southeast region) at DePuy Spine, Inc. from January 2003 to December 2005. Mr. Rydin also served as Vice President of Sales at Orquest, Inc. from December 2001 to January 2003, Director of Sales at Symphonix Devices, Inc. from April 2000 to December 2001 and Director of Sales at General Surgical Innovations, Inc. from October 1996 to March 2000. Mr. Rydin also has served in various executive and leadership sales roles at General Surgical Innovations, Baxter Healthcare, US Surgical Corporation and Xerox. He currently serves as director of DuraStat, LLC, which has created a unique device for dural repair. Mr. Rydin received a B.A. degree in Social Ecology from the University of California, Irvine.

What is the salary of Jeffrey Rydin?

As the Director of Alphatec Inc, the total compensation of Jeffrey Rydin at Alphatec Inc is $110,788. There are 11 executives at Alphatec Inc getting paid more, with Patrick Miles having the highest compensation of $7,960,100.

How old is Jeffrey Rydin?

Jeffrey Rydin is 53, he's been the Director of Alphatec Inc since 2017. There are 10 older and 14 younger executives at Alphatec Inc. The oldest executive at Alphatec Holdings Inc is Ward Woods, 77, who is the Independent Director.

What's Jeffrey Rydin's mailing address?

Jeffrey's mailing address filed with the SEC is C/O ALPHATEC SPINE, INC., 1950 CAMINO VIDA ROBLE, CARLSBAD, CA, 92008.

Insiders trading at Alphatec Inc

Over the last 18 years, insiders at Alphatec Inc have traded over $1,216,108,242 worth of Alphatec Inc stock and bought 24,460,197 units worth $141,338,962 . The most active insiders traders include Mortimer Iii Berkowitz, John Foster et Llc Hgp. On average, Alphatec Inc executives and independent directors trade stock every 24 days with the average trade being worth of $1,610,824. The most recent stock trade was executed by Evan Bakst on 23 August 2024, trading 35,000 units of ATEC stock currently worth $201,600.

What does Alphatec Inc do?

as a medical technology company, we improve lives by providing innovative spine surgery solutions through our relentless pursuit of superior outcomes. we are dedicated to the design, development, launch and the delivery of spinal fusion products. we seek to accomplish this by working with spine surgeons to design and develop products and systems that address the entire spinal fusion procedure in the most effective and efficient way possible. our product designs and platforms provide innovation through a focus on simplifying procedures for the surgeon with the ultimate objective of superior outcomes. alphatec spine is seeking growth through innovation and continually developing technologies that will have a greater positive impact on patient care and outcomes. please visit our website for more information: www.alphatecspine.com

Complete history of Mr. Rydin stock trades at Alphatec Inc et Nuvasive Inc

Alphatec Inc executives and stock owners

Alphatec Inc executives and other stock owners filed with the SEC include:

• Patrick Miles,
  Chairman of the Board, President, Chief Executive Officer
• David Sponsel,
  Executive Vice President - Sales
• Jeffrey Black,
  Chief Financial Officer, Executive Vice President
• Patrick S. Miles,
  Exec. Chairman, CEO & Pres
• Craig Hunsaker,
  Executive Vice President - People & Culture, General Counsel
• David P. Sponsel,
  Exec. VP of Sales
• Craig E. Hunsaker,
  Exec. VP of People & Culture, Corp. Sec. and Gen. Counsel
• Donald Williams,
  Independent Director
• Ward Woods,
  Independent Director
• Quentin Blackford,
  Independent Director
• David Mowry,
  Independent Director
• Jeffrey Rydin,
  Director
• James Tullis,
  Independent Director
• Jason Hochberg,
  Independent Director
• Evan Bakst,
  Independent Director
• Karen McGinnis,
  Independent Director
• Josh Berg,
  IR Contact Officer
• David Pelizzon,
  Director
• Mortimer Berkowitz,
  Lead Independent Director
• Mark Ojeda,
  Executive Vice President - Cervical & Biologics
• Kelli Howell,
  Executive Vice President - Clinical Strategies
• Eric Dasso,
  Executive Vice President - Adjunctive Technologies
• Brian Snider,
  Executive Vice President - Marketing and Development
• Mark D. Ojeda,
  Exec. VP of Cervical & Biologics
• Kelli Mari Howell,
  Exec. VP of Clinical Strategies
• Dr. Luiz Pimenta,
  Chief Medical Officer
• Jonathan Allen,
  Exec. VP of Commercial Operations
• Brian R. Snider,
  Exec. VP of Marketing
• Scott Lish,
  Sr. VP of R&D
• J. Todd Koning,
  Chief Financial Officer
• Terry M. Rich,
  President & COO
• Leslie H Cross,
  Director
• Dennis Nelson,
  VP, Finance and Controller
• Stephen Oneil,
  Director
• Siri S Marshall,
  Director
• R Ian Molson,
  Director
• James Corbett,
  President and CEO
• Jonathan Allen,
  EVP, Commerical Operations
• Michael Joseph Plunkett,
  Chief Operating Officer
• Michael O'neill,
  CFO and Vice President
• John Foster,
  Director
• Ebun Garner,
  VP, Legal Affairs & Compliance
• Jennifer N. Pritzker,
  10% owner
• David M Demski,
  
• Keith Valentine,
  
• Healthcare Partners, Llc Se...,
  
• Mitsuo Asai,
  President, Alphatec Pacific
• Tom C Davis,
  Director
• James R Glynn,
  Director
• Rohit M Desai,
  Director
• Luke T Faulstick,
  Director
• William Patrick Ryan,
  Chief Operating Officer
• Partners Ii L P Healthpoint...,
  10% owner
• Ii, Llc Hgp,
  10% owner
• Ross Simmonds,
  Senior VP, Sales & Marketing
• Stephen Lubischer,
  VP, Sales
• Reinecke Steven,
  VP, Research & Development
• Richard Ravitch,
  Director
• Oliver Burckhardt,
  President, International
• Kermit P. Stott,
  VP, Operations
• Co Invest Vehicle Ii, L.P. ...,
  10% owner
• Peter C Wulff,
  CFO, VP and Treasurer
• Dirk Kuyper,
  President and CEO
• Brian Plotkin,
  VP, Information Technology
• Jens Peter Timm,
  VP, Research and Development
• Stephen Hochschuler,
  Director
• Corp Chubb,
  10% owner
• Partners Lp Healthpoint Cap...,
  10% owner
• Llc Hgp,
  10% owner
• Ii, Llchealthpointcapital P...,
  
• Herbert J Bellucci,
  VP, Manufacturing
• Stephen T D Dixon,
  CFO, VP and Treasurer
• Vicky Romanoski,
  Chief Admin Ofcr, VP & Scrty
• Insurance Co Federal,
  10% owner
• Daniel Lacienski,
  Executive VP, Operations
• Kimberly Bradshaw,
  VP, Physician Services
• Steven Yasbek,
  CFO, Treasurer and V.P.
• Shunshiro Yoshimi,
  
• Ronald Hiscock,
  President & CEO
• Scott Weise,
  VP, Business Dev. & Marketing
• Trent Northcutt,
  VP, Sales
• John Todd Koning,
  CHIEF FINANCIAL OFFICER
• Marie Meynadier,
  
• Elizabeth Ann Altman,
  
• Paul Segal,
  
• Tyson Eliot Marshall,
  GENERAL COUNSEL & CORP. SEC.
• Andy Barnett,
  Director
• Scott Lish,
  CHIEF OPERATING OFFICER